bioMérieux organizes the First World Forum on Healthcare-Associated Infections (HAI). This Forum will bring together around fifty international experts at the Mérieux Foundation Conference Center (Les Pensières, Veyrier-du-Lac, France) from June 4th to 5th 2007.
AdvanDx and bioMérieux Partner to Provide Rapid Results for Bloodstream Infections
22 Maggio, 2007
In order to provide faster identification of bloodstream pathogens, bioMérieux (Euronext: BIM) has agreed with AdvanDx, Inc. to sign an exclusive distribution agreement for the United States for AdvanDx’s PNA FISH™ rapid diagnostic tests. These tests will be displayed at bioMérieux’s booth from the opening of the American Society of Microbiology (ASM) in Toronto on May 22.
bioMérieux and LabTech Systems sign exclusive worldwide license agreement for innovative robotic microbiological instrumentation
18 Aprile, 2007
LabTech Systems Ltd (ASX: LBT), an Australian health care equipment and services company, and bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announced today that they have signed an exclusive worldwide license agreement for LabTech Systems’ automated pre-poured media (PPM) streaker known as MicroStreak®.
bioMérieux Launches VIDAS® B·R·A·H·M·S PCT, a Procalcitonin Measurement Test Allowing Early Detection of Severe Bacterial Infections
30 Marzo, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B·R·A·H·M·S PCT. This new, CE approved test, was developed following the licensing agreement signed with B·R·A·H·M·S, enabling bioMérieux to develop, produce and market a test for measuring procalcitonin (PCT) levels. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
bioMérieux and ExonHit Therapeutics initiate their third diagnostic program
04 Gennaio, 2007
Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.
